Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Emerging Burden
Published: 2022-12-22
Page: 206-217
Issue: 2022 - Volume 5 [Issue 2]
Saima Batool *
Nishtar Medical University, Pakistan.
Kimberly Morton Cuthrell
Saint James School of Medicine, Illinois, United States of America.
Nikolaos Tzenios
Public Health and Medical Research, Charisma University, Grace Bay, Turks and Caicos Islands.
Zaid Shehryar
Brooklyn College Academy High School, United States.
*Author to whom correspondence should be addressed.
Abstract
Liver is the largest solid organ in the body that performs over 100 functions. It removes the toxins and waste products from the blood stream, maintains healthy blood sugar levels, regulates blood clotting; synthesize essential body proteins and other vital functions. The liver has a big impact on lipid metabolism. Depending on the species, the liver is essentially the hub of fatty acid synthesis and lipid circulation through lipoprotein formation. The buildup of lipid droplets inside the hepatocytes ultimately results in hepatic steatosis, which can be brought on by a variety of dysfunctions, including alterations in -oxidation, very low density lipoprotein secretion, and pathways involved in the generation of fatty acids. Increased blood levels of non-esterified fatty acids could possibly be a major factor in the development of fatty liver disease. In many developed countries, non-alcoholic fatty liver disease (NAFLD) is quickly becoming the main cause of chronic liver disease and hepatocellular carcinoma (HCC) which poses significant difficulties for the detection, diagnosis, and treatment of HCC. In this review, an overview is presented of the most recent research on the epidemiology, etiology of liver cirrhosis, risk factors, and prognosis of NAFLD-HCC patients. There is a significant need to emphasize the need for NAFLD-associated HCC prevention and offer some insight into the unresolved barriers and difficulties surrounding patient surveillance strategies.
Keywords: Hepatocellular carcinoma (HCC), non-alcoholic fatty liver disease-hepatocellular carcinoma (NAFLD-HCC), reactive oxygen species (ROS), non-alcoholic fatty liver disease (NAFLD), comorbidities
How to Cite
Downloads
References
Barrangou R. The roles of CRISPR-Cas systems in adaptive immunity and beyond. Current Opinion in Immunology. 2015; 32:36–41.
Redman M, King A, Watson C, King D. What is CRISPR/Cas9. Archives of Disease in Childhood: Education and Practice Edition. 2016;101 (4):213–215.
Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315 (5819):1709–1712.
Marraffini LA, Sontheimer EJ. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science. 2008;322 (5909):1843–1845.
Hille F, Richter H, Wong SP, Bratovič M, Ressel S, Charpentier E. The Biology of CRISPR-Cas: Backward and Forward. Cell. 2018;172 (6):1239–1259.
Makarova KS, Haft DH, Barrangou R, Brouns SJJ, Charpentier E, Horvath P, Moineau S, Mojica FJM, Wolf YI, Yakunin AF, Oost JV, Koonin EV. Evolution and classification of the CRISPR-Cas systems. Nature Review Microbiology. 2011;9(6): 467–477.
Kaminski MM, Abudayyeh OO, Gootenberg JS, Zhang F, Collins JJ. CRISPR-based diagnostics. Nature Biomedical Engineering. 2021;643–656.
Lander ES. The Heroes of CRISPR. CELL. 2016;164: 18-28.
Mubthasima PP, Pande K, Prakash R, Kannan A. CRISPR Cas/Exosome Based Diagnostics: Future of Early Cancer Detection. in U. Bacha (ed). Rural Health. IntechOpen, London; 2021.
Available:http://dx.doi.org/10.5772/intechopen.99900
Terns MP, Terns RM. CRISPR-Based Adaptive Immune Systems. Current Opinion in Microbiology. 2011;14(3): 321–327.
Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Delivery. 2018;25(1):1234–1257.
Garneau JE, Dupuis MÈ, Villion M, Romero DA, Barrangou R, Boyaval P, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. 2010;468 (7320):67–71.
Aliyari R, Ding SW. RNA-based viral immunity initiated by the Dicer family of host immune receptors. Immunological Reviews. 2009;227(1):176–188.
Gong S, Zhang S, Lu F, Pan W, Li N, Tang B. CRISPR/Cas-Based In Vitro Diagnostic Platforms for Cancer Biomarker Detection. Analytical Chemistry. 2021;93:11899−11909
Shivram H, Cress BF, Knott GJ, Doudna JA. Controlling and enhancing CRISPR systems. Nature Chemical Biology. 2021;17(1):10–19.
Hillary VE, Ceasar SA. A Review on the Mechanism and Applications of CRISPR/Cas9/Cas12/ Cas13/Cas14 Proteins Utilized for Genome Engineering. Molecular Biotechnology;2022.
Jiang F, Doudna JA. CRISPR–Cas9 Structures and Mechanisms. Annual Review of Biophysics. 2017;46:505–529.
O’Connell MR, Oakes BL, Sternberg SH, East-Seletsky A, Kaplan M, Doudna JA. Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature. 2014; 516(7530):263–266.
Cao H, Wang Y, Zhang N, Xia S, Tian P, Lu L, Du J, Du Y. Progress of CRISPR-Cas13 Mediated Live-Cell RNA Imaging and Detection of RNA-Protein Interactions. Frontiers in Cell and Developmental Biology. 2022;10:866820.
Xue Y, Chen Z, Zhang W, Zhang J. Engineering CRISPR/Cas13 System against RNA Viruses: From Diagnostics to Therapeutics. Bioengineering. 2022;9:291
Yan WX, Chong S, Zhang H, Makarova KS, Koonin EV, Cheng DR, et al. Cas13d is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein. Molecular Cell. 2018;70(2): 327–339.
Abudayyeh OO, Gootenberg JS, Franklin B, Koob J, Kellner MJ, Ladha A, et al. A Cytosine Deaminase for Programmable Single-Base RNA Editing. Science. 2019;365 (6451):382–386.
Xu C, Zhou Y, Xiao Q, He B, Geng G,Wang Z, et al. Programmable RNA Editing with Compact CRISPR-Cas13 Systems from Uncultivated Microbes. Nat. Methods. 2021;18 (5):499–506.
Burstein D, Harrington LB, Strutt SC, Probst AJ, Anantharaman K, Thomas BC, Banfield JF. New CRISPR–Cas systems from uncultivated microbes. Nature. 2017;542(7640):237–241.